|
US2019062443A1
|
|
Highly potent antibodies binding to death receptor 4
|
|
US2019352386A1
|
|
Highly potent monoclonal antibodies to angiogenic factors
|
|
WO2013173745A1
|
|
Monoclonal antibodies to macrophage stimulating protein
|
|
US2015110788A1
|
|
Bispecific antibodies with an fgf2 binding domain
|
|
EP3783024A1
|
|
Monoclonal antibodies to fibroblast growth factor receptor 2
|
|
BRPI0912035A2
|
|
monoclonal antibody, pharmaceutical composition, use of a pharmaceutical composition, mouse mab in chimeric or humanized form, and humanized antibody
|
|
WO2009126840A1
|
|
Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
|
|
TW201002346A
|
|
Combination of HGF inhibitor and EGF inhibitor to treat cancer
|
|
TW200948380A
|
|
Combination of HGF inhibitor and PTEN agonist to treat cancer
|
|
CN103172736A
|
|
Humanized monoclonal antibodies to hepatocyte growth factor
|
|
CN101511386A
|
|
Methods of treating brain tumors with antibodies
|
|
US7220410B2
|
|
Monoclonal antibodies to hepatocyte growth factor
|
|
NZ550324A
|
|
Monoclonal antibodies to hepatocyte growth factor
|
